Literature DB >> 16301720

Value of Doppler sonography for predicting clinical outcome after renal artery revascularization in atherosclerotic renal artery stenosis.

Angeles García-Criado1, Rosa Gilabert, Carlos Nicolau, María Isabel Real, Xavier Muntañá, Jordi Blasco, Sergi Ganau, Concepción Brú.   

Abstract

OBJECTIVE: The purpose of this study was to prospectively evaluate the usefulness of Doppler sonography for predicting blood pressure and renal function improvement after percutaneous renal angioplasty in patients with unilateral atherosclerotic renal artery stenosis.
METHODS: Thirty-six patients with successfully revascularized unilateral atherosclerotic renal artery stenosis were included. Patients were evaluated by Doppler sonography before treatment, with the resistive index (RI) and acceleration being measured in both kidneys. Blood pressure, number of antihypertensive drugs, and serum creatinine concentration were assessed before treatment and thereafter during a 23 +/- 15-month (mean +/- SD) period.
RESULTS: In 20 of the 36 patients (55%), the RI was less than 0.80 before revascularization. After treatment, blood pressure improved in 17 (85%) of those 20 patients and improved in 8 (50%) of 16 patients with an RI of greater than 0.80 (P < .05). Twenty-five patients had renal insufficiency pretreatment, and 11 (44%) had a baseline RI of less than 0.80. Improvement in renal function after angioplasty was shown in 5 (45%) of these 11 patients and in 4 (28.5%) of 14 in the group with high RI (P > .05, not significant). On analysis of acceleration, blood pressure improved in 9 (69%) of 13 patients with acceleration of greater than 3 m/s(2) and in 16 (69.5%) of 23 with acceleration of less than 3 m/s(2) (P > .05). In patients with renal insufficiency, 5 (50%) of 10 cases with normal baseline acceleration and 4 (27%) of 15 with low acceleration showed improvement in renal function (P > .05).
CONCLUSIONS: An elevated RI should not exclude patients from a revascularization procedure because, although renal RI does correlate with blood pressure response to revascularization, it is not a useful parameter in predicting renal function outcome. Acceleration has no prognostic value.

Entities:  

Mesh:

Year:  2005        PMID: 16301720     DOI: 10.7863/jum.2005.24.12.1641

Source DB:  PubMed          Journal:  J Ultrasound Med        ISSN: 0278-4297            Impact factor:   2.153


  6 in total

1.  Hypertension and reduced renal function in an 83-year-old patient.

Authors:  Andrea Ungar; Lorella Lambertucci; Chiara Agresti; Riccardo Pini; Maria Boddi; Maria Consuelo Valentini; Gianfranco Parati; Pietro Amedeo Modesti
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

Review 2.  Diagnostic criteria for renovascular disease: where are we now?

Authors:  Sandra M S Herrmann; Stephen C Textor
Journal:  Nephrol Dial Transplant       Date:  2012-07       Impact factor: 5.992

Review 3.  How should we define appropriate patients for percutaneous transluminal renal angioplasty treatment?

Authors:  Yoshio Iwashima; Toshihiko Ishimitsu
Journal:  Hypertens Res       Date:  2020-06-22       Impact factor: 3.872

4.  Stenting for renal-artery stenosis.

Authors:  Timothy P Murphy; Lance D Dworkin; Christopher J Cooper
Journal:  N Engl J Med       Date:  2014-05-08       Impact factor: 91.245

5.  Doppler ultrasound and renal artery stenosis: An overview.

Authors:  A Granata; F Fiorini; S Andrulli; F Logias; M Gallieni; G Romano; E Sicurezza; C E Fiore
Journal:  J Ultrasound       Date:  2009-10-12

6.  Predictive role of renal resistive index for clinical outcome after revascularization in hypertensive patients with atherosclerotic renal artery stenosis: a monocentric observational study.

Authors:  Rosa Maria Bruno; Elena Daghini; Daniele Versari; Melania Sgrò; Michela Sanna; Luigi Venturini; Caterina Romanini; Irene Di Paco; Isabella Sudano; Roberto Cioni; Lilach O Lerman; Lorenzo Ghiadoni; Stefano Taddei; Stefania Pinto
Journal:  Cardiovasc Ultrasound       Date:  2014-02-20       Impact factor: 2.062

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.